Hopewell Therapeutics will use the funding to advance the development of genomic medicines. Credit: khawfangenvi16 via Shutterstock.com.

Biotechnology company Hopewell Therapeutics has raised $25m in seed financing to accelerate the development of next-generation lipid nanoparticles for targeted delivery of genomic medicines.

Participants in the funding round, which was raised in multiple tranches, include IMO Capital, 5Y Capital, BOPU Capital, WS Investments, Mass Ave Capital and HIKE Capital.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The company will use the funds to advance the development of genomic medicines, using its differentiated tissue-targeted lipid nanoparticle (ttLNP) platform.

Hopewell Therapeutics is engaged in discovering, synthesising and developing advanced ttLNPs to provide next-generation genomic medicines.

The development will be advanced through both internal pipeline programmes and external collaborations.

See Also:

The ttLNP platform can deliver a range of high-impact genomic payloads, including gene editing, siRNA, mRNA, DNA and gene-writing apparatus, to tissues, cells and organs.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Hopewell Therapeutics president and CEO Louis Brenner stated: “Hopewell Therapeutics seeks to redefine the non-viral delivery space for novel genomic medicines by designing systemically administered LNPs to specifically target extrahepatic tissues and cells throughout the body.

“The ground-breaking research and intellectual property in LNP [lipid nanoparticle] design and delivery established by Professor Xu over the last decade provide a solid foundation for Hopewell to develop our own internal pipeline, initially targeting diseases of the lung while concurrently exploring the potential of our ttLNP platform for patients with unmet needs in oncology, infectious diseases, rare genetic diseases and neurological disorders.”